Fu J-F, Liang L, Zou C-C, Hong F, Wang C-L, Wang X-M, Zhao Z-Y
Department of Endocrinology, the Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Int J Obes (Lond). 2007 Jan;31(1):15-22. doi: 10.1038/sj.ijo.0803453. Epub 2006 Sep 5.
We aimed to evaluate the prevalence of metabolic syndrome (MS) in a group of obese children and adolescents in Zhejiang in the south of China, and to compare risk factors such as insulin resistance, adiponectin level and impaired glucose tolerance (IGT) etc with that of simple obese group (SOB) and non-obese healthy group, and also to evaluate the effect of metformin and lifestyle intervention in MS group by up to a 3-month follow-up.
Three hundred and forty eight moderately or severely obese adolescents aged between 7 and 16 years were enrolled. Oral glucose tolerance test (OGTT), biochemical indicators, blood pressure and body mass index (BMI) were assessed in all of them. Three subgroups were selected (MS group, SOB and healthy control). Adiponectin levels, Whole body insulin sensitive index (WBISI), homeostasis model of insulin resistance (HOMA-IR), plasma lipid and blood pressure were compared in these three groups. Thirty out of thirty-six MS subjects with age over 10 years received metformin treatment combined with lifestyle modification.
(1) The prevalence of MS was 10.34% among all obese subjects, which increased with the severity of obesity and reached 22.1% in severely obese children and adolescents. The occurrence of more than one complication reached 72.13%. The incidence of type 2 diabetes and IGT were 1.44 and 1.44% respectively. (2) BMI, waist-to-hip ratio (WHR) and HOMA-IR increased stepwise in the control group, SOB and MS group, whereas serum adiponectin and WBISI decreased stepwise (all P<0.01). Systolic pressure, triglyceride, total cholesterol, low-density lipoprotein cholesterol and postprandial 2-h blood glucose in the MS group increased significantly compared to those in control and SOBs (all P<0.01). A correlation analysis showed that serum levels of adiponectin and WBISI were associated with the components of MS (all P<0.05). (3) After metformin and lifestyle intervention, clinical symptoms were ameliorated, serum adiponectin levels were actually increased and HOMA-IR was dropped in 20/30 MS children who had finished a 3-months follow-up (all P<0.01).
The prevalence of MS in severely obese children and adolescents in Zhejiang area has reached a high level. Insulin resistance and hypoadiponectinemia were found in these MS children. Metformin combined with lifestyle modification was confirmed to be efficient and safe in treating the obese adolescents with MS.
我们旨在评估中国南方浙江省一组肥胖儿童和青少年中代谢综合征(MS)的患病率,并将胰岛素抵抗、脂联素水平和糖耐量受损(IGT)等危险因素与单纯肥胖组(SOB)和非肥胖健康组进行比较,同时通过长达3个月的随访评估二甲双胍和生活方式干预对MS组的影响。
招募了348名7至16岁的中度或重度肥胖青少年。对他们所有人进行口服葡萄糖耐量试验(OGTT)、生化指标、血压和体重指数(BMI)评估。选择了三个亚组(MS组、SOB组和健康对照组)。比较这三组的脂联素水平、全身胰岛素敏感指数(WBISI)、胰岛素抵抗稳态模型(HOMA-IR)、血脂和血压。36名年龄超过10岁的MS受试者中有30人接受了二甲双胍治疗并结合生活方式改善措施。
(1)所有肥胖受试者中MS的患病率为10.34%,其随肥胖严重程度增加,在重度肥胖儿童和青少年中达到22.1%。一种以上并发症的发生率达到72.13%。2型糖尿病和IGT的发生率分别为1.44%和1.44%。(2)对照组、SOB组和MS组的BMI、腰臀比(WHR)和HOMA-IR呈逐步升高,而血清脂联素和WBISI呈逐步降低(均P<0.01)。与对照组和SOB组相比,MS组的收缩压、甘油三酯、总胆固醇、低密度脂蛋白胆固醇和餐后2小时血糖显著升高(均P<0.01)。相关性分析表明,血清脂联素水平和WBISI与MS的各组分相关(均P<0.05)。(3)经过二甲双胍和生活方式干预后,30名完成3个月随访的MS儿童的临床症状得到改善,血清脂联素水平实际升高,HOMA-IR下降(均P<0.01)。
浙江地区重度肥胖儿童和青少年中MS的患病率已达到较高水平。这些MS儿童存在胰岛素抵抗和低脂联素血症。二甲双胍联合生活方式改善措施被证实对治疗患有MS的肥胖青少年有效且安全。